John W. Day, Ph.D.
Affiliations: | 2013 | Anthropology | Harvard University, Cambridge, MA, United States |
Area:
Arab StudiesGoogle:
"John Day"Parents
Sign in to add mentor| Steve Caton | grad student | 2013 | Harvard | |
| (In the City, Out of Place: Dispossession and the Economics of Belonging in Southeastern Turkey.) | ||||
Collaborators
Sign in to add collaborator| Alex Chia Yu Chang | collaborator | 2014- | Stanford (Chemistry Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Coratti G, Lucibello S, Pera MC, et al. (2020) Gain and loss of abilities in type II SMA: A 12-month natural history study. Neuromuscular Disorders : Nmd |
| Finkel RS, Day JW, De Vivo DC, et al. (2020) RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases |
| Tao F, Beecham GW, Rebelo AP, et al. (2019) Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. Journal of Neuromuscular Diseases |
| Tao F, Beecham GW, Rebelo AP, et al. (2019) Variation in SIPA1L2 is Correlated with Phenotype Modification in CMT Type 1A. Annals of Neurology |
| Pera MC, Coratti G, Mazzone ES, et al. (2019) Revised Upper Limb Module for Spinal Muscular Atrophy: 12 month changes. Muscle & Nerve |
| Shell R, Day J, Chiriboga C, et al. (2019) S61 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): preliminary pulmonary and ventilatory findings from the phase 3 study (STR1VE) Thorax. 74 |
| Day JW, Chiriboga CA, Crawford TO, et al. (2019) 066 Avxs-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): pivotal phase 3 study (STR1VE) update Journal of Neurology, Neurosurgery & Psychiatry. 90: A22.1-A22 |
| Day JW, Chiriboga CA, Crawford TO, et al. (2019) 250 AVXS-101 phase 3 study in spinal muscular atrophy type 1 Journal of Neurology, Neurosurgery, and Psychiatry. 90 |
| Ramsey D, Scoto M, Mayhew A, et al. (2019) P.220The revised Hammersmith scale (RHS) for spinal muscular atrophy: longitudinal trajectories in a large international cohort of patients with type 2 and 3 SMA Neuromuscular Disorders. 29 |
| Wang ET, Treacy D, Eichinger K, et al. (2018) Transcriptome alterations in myotonic dystrophy skeletal muscle and heart. Human Molecular Genetics |